Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated:  5/2/2016
Novartis Investigative Site
mi
from
Bruxelles,
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Status: Enrolling
Updated: 5/2/2016
Novartis Investigative Site
mi
from
Bruxelles,
Click here to add this to my saved trials
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Tucson, AZ
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
La Jolla, CA
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Santa Monica, CA
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Aurora, CO
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Tampa, FL
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Atlanta, GA
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Park Ridge, IL
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
St. Louis, MO
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Morristown, NJ
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Morristown, NJ
Click here to add this to my saved trials
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
New York, NY
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Columbus, OH
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Nashville, TN
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated:  5/4/2016
Clinical Research Facility
mi
from
Dallas, TX
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
An Open-Label, Multicenter, Phase II Study Of Continuous Oral Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Status: Enrolling
Updated: 5/4/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine
An Exploratory Study of Adjuvant Therapy of Pegylated Interferon-Alfa 2b Plus Melanoma Peptide Vaccine in Patients With Resected, Intermediate-Thickness, Node-Negative Melanoma
Status: Enrolling
Updated:  5/5/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine
An Exploratory Study of Adjuvant Therapy of Pegylated Interferon-Alfa 2b Plus Melanoma Peptide Vaccine in Patients With Resected, Intermediate-Thickness, Node-Negative Melanoma
Status: Enrolling
Updated: 5/5/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma
Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma
Status: Enrolling
Updated:  5/5/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma
Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma
Status: Enrolling
Updated: 5/5/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes
Status: Enrolling
Updated:  5/11/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 TCR-Gene Engineered Lymphocytes
Status: Enrolling
Updated: 5/11/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma
A Phase I Trial for the Evaluation of the In Vivo Persistence of Adoptively-transferred Tumor-Infiltrating Lymphocytes Cultured With a Pharmacologic Inhibitor of AKT in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  5/12/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma
A Phase I Trial for the Evaluation of the In Vivo Persistence of Adoptively-transferred Tumor-Infiltrating Lymphocytes Cultured With a Pharmacologic Inhibitor of AKT in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 5/12/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma
A Feasibility and Toxicity Study of a Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Secreting Allogeneic Melanoma Vaccine Administered Alone or in Combination With Cyclophosphamide in Subjects With Surgically Resected At-Risk Melanoma
Status: Enrolling
Updated:  5/23/2016
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma
A Feasibility and Toxicity Study of a Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Secreting Allogeneic Melanoma Vaccine Administered Alone or in Combination With Cyclophosphamide in Subjects With Surgically Resected At-Risk Melanoma
Status: Enrolling
Updated: 5/23/2016
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
Status: Enrolling
Updated:  6/1/2016
The Angeles Clinic & Research Institute
mi
from
Los Angeles, CA
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
Status: Enrolling
Updated: 6/1/2016
The Angeles Clinic & Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
Status: Enrolling
Updated:  6/1/2016
UCLA
mi
from
Los Angeles, CA
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
Status: Enrolling
Updated: 6/1/2016
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
Status: Enrolling
Updated:  6/1/2016
Columbia University Medical Center
mi
from
New York, NY
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
Status: Enrolling
Updated: 6/1/2016
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
Status: Enrolling
Updated:  6/1/2016
Cross Cancer Institute
mi
from
Edmonton,
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
Status: Enrolling
Updated: 6/1/2016
Cross Cancer Institute
mi
from
Edmonton,
Click here to add this to my saved trials
An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
A Phase I Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
Status: Enrolling
Updated:  6/7/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
A Phase I Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
Status: Enrolling
Updated: 6/7/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
A Phase I Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
Status: Enrolling
Updated:  6/7/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
A Phase I Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
Status: Enrolling
Updated: 6/7/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
A Phase I Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
Status: Enrolling
Updated:  6/7/2016
Massachusetts General Hospital
mi
from
Boston, MA
An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
A Phase I Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
Status: Enrolling
Updated: 6/7/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
A Phase II Study of SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Status: Enrolling
Updated:  6/8/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
A Phase II Study of SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Status: Enrolling
Updated: 6/8/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
A Phase II Study of SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Status: Enrolling
Updated:  6/8/2016
Massachusetts General Hospital
mi
from
Boston, MA
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
A Phase II Study of SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Status: Enrolling
Updated: 6/8/2016
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
A Phase II Study of SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Status: Enrolling
Updated:  6/8/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
A Phase II Study of SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Status: Enrolling
Updated: 6/8/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
A Phase II Study of SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Status: Enrolling
Updated:  6/8/2016
Vanderbilt University
mi
from
Nashville, TN
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
A Phase II Study of SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Status: Enrolling
Updated: 6/8/2016
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
A Phase II Study of SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Status: Enrolling
Updated:  6/8/2016
Washington University, St. Louis
mi
from
St. Louis, MO
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
A Phase II Study of SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Status: Enrolling
Updated: 6/8/2016
Washington University, St. Louis
mi
from
St. Louis, MO
Click here to add this to my saved trials
Evaluation of Technetium Tc 99m Tilmanocept (Lymphoseek®) Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT and SPECT/CT Imaging
Evaluation of Technetium Tc 99m Tilmanocept Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT/CT Imaging.
Status: Enrolling
Updated:  6/13/2016
San Francisco General Hospital
mi
from
San Francisco, CA
Evaluation of Technetium Tc 99m Tilmanocept (Lymphoseek®) Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT and SPECT/CT Imaging
Evaluation of Technetium Tc 99m Tilmanocept Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT/CT Imaging.
Status: Enrolling
Updated: 6/13/2016
San Francisco General Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Comparison of Interventions to Teach Melanoma Patients Skin Self-examination
A Comparison of Interventions to Teach Melanoma Patients Skin Self-examination
Status: Enrolling
Updated:  6/14/2016
Northwestern University Department of Dermatology
mi
from
Chicago, IL
A Comparison of Interventions to Teach Melanoma Patients Skin Self-examination
A Comparison of Interventions to Teach Melanoma Patients Skin Self-examination
Status: Enrolling
Updated: 6/14/2016
Northwestern University Department of Dermatology
mi
from
Chicago, IL
Click here to add this to my saved trials
Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
Randomized Phase II Neoadjuvant Study of Temozolomide Alone or With Pegylated Interferon-alpha 2b in Patients With Resectable American Joint Committee on Cancer (AJCC) Stage IIIB/IIIC or Stage IV (M1a) Metastatic Melanoma
Status: Enrolling
Updated:  6/16/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
Randomized Phase II Neoadjuvant Study of Temozolomide Alone or With Pegylated Interferon-alpha 2b in Patients With Resectable American Joint Committee on Cancer (AJCC) Stage IIIB/IIIC or Stage IV (M1a) Metastatic Melanoma
Status: Enrolling
Updated: 6/16/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Status: Enrolling
Updated:  6/16/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Status: Enrolling
Updated: 6/16/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated:  6/28/2016
University of Arizona Cancer Center
mi
from
Tucson, AZ
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated: 6/28/2016
University of Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated:  6/28/2016
Wilshire Oncology Medical Group
mi
from
LaVerne, CA
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated: 6/28/2016
Wilshire Oncology Medical Group
mi
from
LaVerne, CA
Click here to add this to my saved trials
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated:  6/28/2016
Angeles Clinic & Rsch Inst
mi
from
Los Angeles, CA
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated: 6/28/2016
Angeles Clinic & Rsch Inst
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated:  6/28/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated: 6/28/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated:  6/28/2016
San Francisco Oncology Associates
mi
from
San Francisco, CA
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated: 6/28/2016
San Francisco Oncology Associates
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated:  6/28/2016
Local Institution
mi
from
To come, CT
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated: 6/28/2016
Local Institution
mi
from
To come, CT
Click here to add this to my saved trials
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated:  6/28/2016
Baptist Cancer Institute
mi
from
Jacksonville, FL
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated: 6/28/2016
Baptist Cancer Institute
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated:  6/28/2016
University of Chicago
mi
from
Chicago, IL
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated: 6/28/2016
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated:  6/28/2016
Indiana Oncology Hematology Consultants
mi
from
Indianapolis, IN
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated: 6/28/2016
Indiana Oncology Hematology Consultants
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated:  6/28/2016
Washington University School of Medicine
mi
from
Saint Louis, MO
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated: 6/28/2016
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated:  6/28/2016
St Joseph Oncology
mi
from
St Joseph, MO
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated: 6/28/2016
St Joseph Oncology
mi
from
St Joseph, MO
Click here to add this to my saved trials
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated:  6/28/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated: 6/28/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated:  6/28/2016
Carolinas Medical Center
mi
from
Charlotte, NC
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Multi-Center, Open-Label, Phase II Study of Ipilimumab (MDX-010 Extended-Treatment Monotherapy or Follow-up for Patients Previously Enrolled in Ipilimumab (MDX-010) Protocols.
Status: Enrolling
Updated: 6/28/2016
Carolinas Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials